Skip to main content Accessibility help
×
Home

Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections

  • Robert J. Woods (a1), Twisha S. Patel (a2), Jerod L. Nagel (a2), Duane W. Newton (a3) and Andrew F. Read (a4)...

Abstract

We report daptomycin minimum inhibitory concentrations (MICs) for vancomycin-resistant Enterococcus faecium isolated from bloodstream infections over a 4-year period. The daptomycin MIC increased over time hospital-wide for initial isolates and increased over time within patients, culminating in 40% of patients having daptomycin-nonsusceptible isolates in the final year of the study.

Infect Control Hosp Epidemiol 2018;39:226–228

Copyright

Corresponding author

Address correspondence to Robert J. Woods, MD, PhD, 5510C MSRB I, SPC 5680; 1150 W. Medical Center Dr, Ann Arbor, MI 48109-5680 (robertwo@med.umich.edu).

Footnotes

Hide All

PREVIOUS PRESENTATION: These results were previously presented as poster number D-1176 at the 55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17, 2015, in San Diego, California.

Footnotes

References

Hide All
1. Kamboj, M, Cohen, N, Gilhuley, K, Babady, NE, Seo, SK, Sepkowitz, KA. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 2011;32:391394.
2. Storm, JC, Diekema, DJ, Kroeger, JS, Johnson, SJ, Johannsson, B. Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible Enterococcus . Antimicrob Resist Infect Control 2012;1:19.
3. Wang, G, Kamalakaran, S, Dhand, A, et al. Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility. Antimicrob Agent Chemother 2014;58:48484854.
4. Judge, T, Pogue, JM, Marchaim, D, et al. Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin. Infect Control Hosp Epidemiol 2012;33:12501254.
5. Shukla, BS, Shelburne, S, Reyes, K, et al. Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: Is it time to change the breakpoint? Clin Infect Dis 2016;62:15141520.
6. Lipsitch, M, Bergstrom, CT, Levin, BR. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci U S A 2000;97:19381943.
7. Lellek, H, Franke, GC, Ruckert, C, et al. Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy. Int J Med Microbiol 2015;305:902909.
8. Pamer, EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 2016;352:535538.
9. Day, T, Read, AF. Does high-dose antimicrobial chemotherapy prevent the evolution of resistance? PLoS Comput Biol 2016;12:e1004689.
10. Munita, JM, Panesso, D, Diaz, L, et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 2012;56:43544359.

Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections

  • Robert J. Woods (a1), Twisha S. Patel (a2), Jerod L. Nagel (a2), Duane W. Newton (a3) and Andrew F. Read (a4)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed